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Abstract: Cow’s milk allergy (CMA) continues to be a growing health concern for infants 
living in Western countries. The long-term prognosis for the majority of affected infants is 
good, with about 80% naturally acquiring tolerance by the age of four years. However, 
recent studies suggest that the natural history of CMA is changing, with an increasing 
persistence until later ages. The pathogenesis of CMA, as well as oral tolerance, is complex 
and not completely known, although numerous studies implicate gut-associated immunity 
and enteric microflora, and it has been suggested that an altered composition of intestinal 
microflora results in an unbalanced local and systemic immune response to food allergens. 
In addition, there are qualitative and quantitative differences in the composition of gut 
microbiota between patients affected by CMA and healthy infants. These findings prompt 
the concept that specific beneficial bacteria from the human intestinal microflora, 
designated probiotics, could restore intestinal homeostasis and prevent or alleviate allergy, 
at least in part by interacting with the intestinal immune cells. The aim of this paper is to 
review what is currently known about the use of probiotics as dietary supplements  
in CMA. 
Keywords: food allergy; probiotics; intestinal microflora; immune system;  
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1. Introduction 
During the last decade, we observed a changing pattern in cow’s milk allergy (CMA), the most 
common food allergy in childhood. An increased prevalence, severity of clinical manifestations and 
risk of persistence was demonstrated in Western countries [1]. In Italy, CMA is responsible for 42% of 
food-induced anaphylaxis in the pediatric population [2].  
Much evidence indicates the development of intestinal microflora as a crucial factor for immune 
system maturation and tolerance acquisition [3]. Early epidemiological studies supported the idea that 
environment-induced alterations in the composition of intestinal microflora play a central role in the 
development of allergic diseases [4]. A recently developed ultra-high-throughput sequencer, called a 
pyrosequencer, allowed sequence-based 16S rRNA profiling of microbiota, confirming the presence of 
gut dysbiosis in allergic infants. In particular, a decrease in selected Firmicutes species and an increase 
in Bacteroidetes species was demonstrated [5]. For more than a century, probiotics have been used as a 
therapeutic/preventive strategy for a variety of gastrointestinal disorders, restoring the intestinal 
microflora. The World Health Organization (WHO)/Food and Agriculture Organization of the United 
Nations (FAO) define probiotics as live microorganisms that, when consumed in adequate amounts as 
part of food or as oral supplements, confer a health benefit on the host [6]. Probiotics research and the 
industry have continued to grow from these early observations, and the global sales of probiotic 
ingredients are expected to reach $31.1 billion by 2015, with an annual growth rate of 7.6% for the 
next few years [7]. Despite the plethora of basic research data, probiotic clinical research in food 
allergy is still in its infancy, but the most recent evidence supports the potential clinical impact derived 
from a manipulation of intestinal microflora as a disrupting strategy to efficiently address the changing 
pattern of CMA. 
2. Oral Tolerance and Intestinal Microflora 
Food antigens and intestinal microflora constitute the majority of the antigen load in the intestine, 
and the ―default‖ reaction of the immune system confronted with them leads to systemic 
unresponsiveness. This phenomenon is known as oral tolerance and is a key feature of intestinal 
immunity [8]. The complex interaction between intestinal contents and immune and non-immune cells 
results in an environment that favors tolerance by the induction of IgA antibodies and  
CD4
+
 T regulatory cells (producing IL-10 and IFN-γ) [3]. This ensures that a homeostatic balance is 
maintained between the intestinal immune system and its antigen load, so that it retains the ability  
to recognize dangerous and harmless antigens as foreign and preserves the integrity of the  
intestinal mucosa.  
The inappropriate immune response to food, which is responsible for food allergy, is the result of a 
deregulation of these crucial processes [9]. An allergic reaction mainly corresponds to the activation of 
Th2 cells against food allergens and occurs in two phases: the first phase corresponds to transport of 
the allergen through the intestinal barrier, its capture by antigen presenting cells, dendritic cells (DCs) 
or enterocytes, and its presentation to naive Th0 cells, which differentiate in the presence of IL-4 into 
Th2 cells. Activated Th2 cells then produce an IL-4 cytokine that enables the production of  
allergen-specific IgE by B-cells [10]. These secreted IgEs then bind to mast cells via the IgE receptor, 
FcεRI. The activation phase corresponds to the degranulation of mast cells after further exposure to the 
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same allergen that links directly with specific IgE on the surface of these cells. This phenomenon 
triggers release of the allergic mediators involved in clinical manifestations of allergy. Recent data 
strongly suggest that gut microbiota is important for oral tolerance development [11] (see Figure 1). 
Figure 1. Intestinal microflora drives oral tolerance development. Under homeostatic 
condition, antigens from selected components of intestinal microflora are acquired in the 
lamina propria and presented in the mesenteric lymphonodes by CD 103
+ 
dendritic cells. 
Through mechanisms mainly involving transforming growth factor (TGF) β and retinoic 
acid, dendritic cells induce the production of gut homing Treg cells. Treg cells actively 
suppress allergic sensitization to food. 
 
Basic research involving microbiology, biology, immunology and genetics is providing interesting 
insights on the delicate network driving to oral tolerance. Studies on germ-free mice revealed a failure 
in the acquisition of tolerance to food proteins. Mice with food allergy exhibit a specific gut microbiota 
signature capable of transmitting disease susceptibility. Transplanted healthy infant microbiota had a 
protective impact on sensitization and CMA in mice. Finally, polymorphisms in or deficiency of 
microbial sensors for bacterial lipopolysaccharide (LPS) (TLR-4) are associated to food  
allergy [12,13]. The spore-forming component of indigenous intestinal microbiota, particularly clusters 
IV and XIVa of the genus Clostridium, promote Treg cell accumulation. Colonization of mice by a 
defined mix of Clostridium strains provides an environment rich in TGF β and affected Foxp3+ Treg 
number and function in the colon. Oral inoculation of Clostridium during the early life of 
conventionally reared mice results in resistance to allergic colitis and systemic immunoglobulin E 
responses in adult mice, suggesting a new therapeutic approach to food allergy [14]. In this light, it is 
important to consider that after four weeks of treatment with the probiotic Lactobacillus rhamnosus 
GG (LGG), it is possible to induce a significant increase in clostridia in milk-hypersensitive subjects [15]. 
3. Probiotics and Their Mechanisms of Action 
Probiotics have pleiotropic effects that occur within the intestinal lumen or within and beyond the 
intestinal mucosa (Table 1). Local influences of probiotics include: hydrolysis of antigenic peptides in 
the gut lumen, modulation of intestinal permeability and reduction of systemic penetration of antigens, 
increased local IgA production and modulation of local inflammation and stimulation of epithelial cell 
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growth and differentiation [16–19]. Some systemic activities consist of anti-inflammatory effects 
mediated by toll-like receptors (TLRs), Th1 skewing of responses to allergens and activation of 
tolerogenic DCs, in addition to T regulatory cell production and tolerance acquisition [20,21]. 
Table 1. Schematic representation of the mechanisms of action of probiotics implicated in 
allergy prevention and treatment. 
 Effects 
Within intestinal lumen  Modulation of intestinal microflora [16] 
 Increased local IgA production [17] 
 Hydrolysis of antigenic peptides [18] 
 
At mucosal level 
 
 Modulation of intestinal permeability [19] 
 Stimulation of cell growth and differentiation [20] 
 
Beyond the intestinal mucosa 
 
 Modulation of innate/adaptive immune system [3] 
 Induction of oral tolerance [3] 
 Impact on the enteric nervous system [21] 
It is becoming evident that completely different effects may be observed, depending on the species 
and the strain of the microorganism used [22]. Recent in vivo studies in healthy human volunteers 
measured the changes in gene transcription profiles to determine the molecular responses that occur in 
the human duodenal mucosa following consumption of probiotic Lactobacillus spp. [23,24].  
These nutrigenomic studies showed that the mucosal responses to distinct Lactobacilli are profoundly 
different, illustrating the specificity of the host responses to specific bacterial strains and/or  
species [24] or even different preparations of the same bacterial strain [23]. Many effects elicited by 
probiotics are dependent on epigenetic modulation of gene expression [25]. These effects could be 
important during critical periods of early development, for example, in the development and 
programming of immune tolerance in the newborn [26]. 
4. Animal Models  
Numerous animal and human studies have been performed to test the potential effects of various 
strains of probiotic bacteria. In this context, one of the most extensively studied probiotics worldwide 
is LGG. Preventive and therapeutic properties of LGG related to atopic diseases, particularly in infants 
with CMA, have been reported [27]. Animal models for food allergy provide an interesting tool to 
perform mechanistic research and to investigate the safety and efficacy of new therapeutic and 
preventive approaches for food allergy. Much progress has been made in recent years in developing an 
animal model of CMA. In particular, animal models for CMA using oral sensitization are mimicking 
the human situation, as children are most likely sensitized to cow’s milk via the oral route. Oral 
tolerance to cow’s milk proteins has been studied in these models aiming to prevent both systemic and 
mucosal responses. In BALB/c mice that were sensitized with cow’s milk proteins via the systemic 
route, oral LGG supplementation favorably modulated immune reactions by shifting Th2-dominated 
trends toward Th1-dominated responses [28].  
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5. Human Studies 
5.1. Prevention of CMA 
Most randomized controlled trials enrolled infants at high risk for developing allergy, which was 
defined as more than one family member having any allergic disease. Most of these studies looked 
primarily at early outcomes of allergic disease, such as eczema. Although atopic eczema is a frequent 
manifestation of CMA [29], it is hard to define a selective preventive effect against this type of food 
allergy. A large number of papers have been published on this topic with conflicting results. 
Differences in study design, populations, probiotic strains and dosages are responsible for these 
discrepancies. Prenatal and postnatal administration of high doses of selected probiotic strains seems to 
be the most promising approach (see Table 2).  
Table 2. Main allergy prevention studies using probiotics. 
Investigators Population Probiotics and doses Prenatal 
administration 
Postnatal 
administration 
Reduction in 
eczema 
References 
Kalliomaki et al. 
(2001, 2002, 2003)  
Mothers with  
≥1 first-degree 
relative (or 
partner) with 
allergic disease 
Lactobacillus rhamnosus GG  
(1 × 1010 CFU/day)  
(only to mother if breast feeding 
post-natally) 
Yes 
2–4 weeks before 
delivery 
Yes 
6 months (only to 
baby if not 
breastfeeding) 
Yes 
at 2 and 4 years 
 
[30–32] 
Rautava et al. 
(2006)  
Need for artificial 
feeding before 
2 months of age 
 
Lactobacillus rhamnosus GG  
(1 × 1010 CFU/day) + 
Bifidobacterium lactis  
(1 × 1010 CFU/ day) added to  
infant formula  
No 
 
Yes 
from <2 months 
(depending on age 
started formula) 
until 12 months 
No 
 
[33] 
Taylor et al.  
(2007) 
Mother with 
positive SPT or 
documented 
allergic disease 
Lactobacillus acidophilus  
(3 × 108 CFU/day) 
No 
 
Yes 
6 months 
direct to infant 
No 
at 1 year 
[34] 
Kukkonen et al. 
(2007, 2009) 
One or both 
parents with 
allergic disease 
Lactobacillus rhamnosus GG and 
LC705 (both 5 × 109 CFU twice 
daily) + Bifidobacterium breve and 
Proprionibacterium freudenreichii 
(both 2 × 109 CFU twice daily) 
Yes 
2–4 weeks before 
delivery 
Yes 
6 months 
direct to infant 
Yes 
At 2 years. 
No effect at 5 years 
(except decrease in 
atopic eczema in 
cesarean-delivered 
children) 
[35,36] 
Abrahamsson et al. 
(2007) 
Families with 
allergic disease 
Lactobacillus reuteri  
(1 × 108 CFU/day) 
 
Yes 
2–4 weeks before 
delivery 
Yes 
12 months 
direct to infant 
No 
At 2 years 
 
[37] 
Kopp et al.  
(2007) 
Pregnant women 
from families with 
≥1 first-degree 
relative with an 
atopic disease 
Lactobacillus rhamnosus GG  
(1 × 1010 CFU/day) to mother if 
breast feeding post-natal for  
3 months, then to the neonates for 
additional 3 months  
Yes 
4–6 weeks before 
delivery 
Yes 
6 months 
direct to infant 
No 
At 2 years 
[38] 
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Table 2. Cont. 
Wickens et al. 
(2008) 
One or both parents 
with allergic disease 
Lactobacillus rhamnosus  
HN001 (1 × 1010 CFU/day) or 
Bifidobacterium lactis  
(1 × 1010 CFU/day) HN019  
Yes 
2–5 weeks before 
delivery 
Yes 
2 years to infant, 
regardless of 
feeding method 
Yes 
at 2 years 
[39] 
Huurre et al. 
(2008) 
Mother with current 
atopic disease 
Lactobacillus rhamnosus GG + 
Bifidobacterium lactis  
(both at 1 × 1010 CFU/day) 
Yes 
from first trimester 
Yes 
end of exclusive 
breastfeeding 
No 
 
[40] 
Soh et al.  
(2009) 
Any first degree 
relative with SPT + 
allergic disease 
Lactobacillus rhamnosus LPR 
(1 × 109 CFU/day) + 
Bifidobacterium longum BL999 
(6 × 108 CFU/day) 
No 
 
Yes 
6 months 
in infant formula 
 
No 
at 1 year 
 
[41] 
Niers et al. 
(2009) 
Atopic disease in 
either mother or 
father plus at least 
one sibling 
Lactococcus lactis W58 + 
Bifidobacterium lactis W52 + 
Bifidobacterium bifidum W23  
(each at: 1 × 109 CFU/day) 
Yes 
6 weeks before 
delivery 
 
Yes 
12 months  
(direct to infant) 
 
Yes 
 
[42] 
West et al. 
(2009) 
Atopic disease in 
either mother or 
sibling 
Lactobacillus paracasei strain  
F19 (1 × 108 CFU/day in  
weaning cereal) 
No Yes 
4–13 months 
during weaning 
Yes [43] 
Dotterud et al. 
(2009) 
Unselected 
population 
Lactobacillus rhamnosus 
GG + Lactobacillus 
acidophilus LA5 + 
Bifidobacterium lactis Bb-12  
(each at 5 × 1010 CFU/day) 
Yes 
from  
36 weeks 
No 
Given to the 
breastfeeding 
mother for  
3 months 
Yes [44] 
Kim et al.  
(2010) 
Pregnant women 
with a family 
history of allergic 
diseases 
Biﬁdobacterium biﬁdum BGN4 + 
Biﬁdobacterium lactis AD011 and 
Lactobacillus acidophilus AD031 
(each at 1.6 × 109 CFU/day) in  
0.72 g of maltodextrin and 0.8 g  
of alpha-corn  
Yes 
4–8 weeks before 
delivery 
Yes 
6 months after 
delivery 
Yes 
at 1 year 
[45] 
Boyle et al. 
(2011) 
Pregnant women 
carrying infants at 
high risk of allergic 
disease 
Lactobacillus rhamnosus GG  
(1.8 × 1010 CFU/day) 
Yes 
from 36 weeks 
gestation until 
delivery 
No No 
at 1 year 
[46] 
Rautava et al. 
(2012) 
Mothers with 
allergic disease 
and atopic 
sensitization 
Lactobacillus rhamnosus LPR + 
Bifidobacterium longum BL999 or 
Lactobacillus paracasei ST11 + 
Bifidobacterium longum BL999 
(each at 1 × 109 CFU/day) 
Yes 
2 months  
before delivery 
Yes 
2 months of  
breast feeding 
Yes [47] 
SPT: skin prick test; CFU: colony-forming unit. 
5.2. Treatment of CMA 
The first objective in the treatment of CMA is the rapid resolution of symptoms. At this time, the 
only proven treatment consists of elimination of cow’s milk protein from the diet. For infants receiving 
standard formulas, a hypoallergenic formula is indicated. Administration of LGG to food-allergic 
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children (age <2 years, challenge-proven and mild-to-moderate eczema) improved the eczema score 
significantly [48]. Studies in infants with eczema who received formulas supplemented with LGG 
showed benefits in decreasing gastrointestinal symptoms [49]. For instance, after a challenge study in 
infants allergic to cow’s milk proteins, fecal IgA levels were detected to be higher, and TNF-α levels 
were lower in the LGG applied group compared to the placebo [50]. Nermes et al. [51] investigated the 
interaction of LGG with skin and intestinal microflora and humoral immunity in infants with atopic 
dermatitis. This study showed a statistically significant decrease of IgA- and IgM-secreting cells one 
month after starting an intervention with extensively hydrolyzed casein formula (eHCF) supplemented 
with LGG. This might indirectly indicate that LGG enhances gut barrier function and accelerates 
immunological maturation in infants with atopic dermatitis. Especially, the finding of significant 
increase in memory B cells in LGG treated infants could be of particular importance [51]. Moreover, 
LGG is able to induce IFN-γ secretion in infants with CMA and in infants with IgE-associated 
dermatitis, but not in infants without CMA. This supports the view that the pattern of intestinal 
microflora may be aberrant in infants with an atopic predisposition, and the beneficial effects of 
probiotics are evident only in this group [52]. The addition of LGG to an eHCF significantly improved 
the recovery of the inflamed colonic mucosa if compared to that obtained with eHCF alone in infants 
with blood in the stool and CMA-induced colitis, as indicated indirectly by greater decreases in fecal 
calprotectin and in the number of infants with persistence of occult blood in stools after 1 month [53]. 
The second objective in the treatment of CMA is tolerance acquisition. Hol, J. et al. [54] showed 
that supplementation of a combination of Lactobacillus casei CRL431and Bifidobacterium lactis  
Bb-12 to an extensively hydrolyzed formula failed to induce additional or accelerated cow’s milk 
(CM) tolerance during 12 months of treatment in infants with CMA. In contrast, we recently 
demonstrated that an eHCF containing LGG was able to accelerate the development of tolerance 
acquisition in infants affected by CMA. Infants (aged 1–12 months), consecutively referred for 
strongly suspected CMA, but still receiving cow’s milk proteins, were invited to participate in the 
study. Subjects were randomly allocated to one of the two groups of dietary interventions: group 1, 
received an eHCF and group 2 received an eHCF containing LGG (at least 1.4 × 10
7
 CFU/100 mL). 
After 12 months, the double-blind placebo-controlled food challenge (DBPCFC) was negative in  
15 of 28 infants in the control group (53.6%) and in 22 of 27 infants receiving the eHCF containing 
LGG (81.5%, p = 0.027). These findings suggest an innovative approach for infants affected by CMA, 
namely an ―active dietotherapy‖ able to reduce the time of tolerance acquisition [55]. 
6. Safety 
The addition of probiotics in formulas used for the management of CMA requires that they be 
proven safe and are well tolerated. According to the European Society of Pediatric Gastroenterology 
and Nutrition (ESPGHAN) and the American Academy of Pediatrics, a formula must be tested in a 
properly designed DBPCFC and can be considered hypoallergenic when demonstrated with  
95% confidence that at least 90% of infants and children with confirmed CMA would have no reaction 
to the formula under double-blind, placebo-controlled conditions. LGG has over 25 years of safe use, 
including administration to preterm infants. Recently, Muraro et al. [56] demonstrated that an eHCF 
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remains hypoallergenic following the addition of LGG, satisfying both the ESPGHAN and American 
Academy of Pediatrics guidelines.  
An emerging problem is the observation that some probiotic compounds that are currently on the 
market may contain hidden allergens of food and may not be safe for subjects with CMA. Thus, more 
accurate screening tests to detect residual food proteins in end products are necessary to assess the 
safety of these products for food allergic patients. For allergic subjects, we would only recommend 
well characterized products with better information on their labels about the content of cow’s  
milk proteins [57]. 
7. Conclusions  
An increasing amount of evidence suggests the role of select probiotics in prevention or treatment 
of CMA. These data support the importance of a ―nutritional immunology approach‖ able not only to 
efficiently cure the symptoms, but also to accelerate tolerance acquisition in children with CMA. 
However, as a result of strain, dose and product specificities and in order to be in agreement with 
recommendations of official and scientific organizations, it is important that randomized, controlled 
trials are performed for each commercialized product.  
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